Acticor Biotech is a clinical stage biotechnology company, founded in 2013, spin-off from the INSERM [French National Institute of Health and Medical Research], developing an innovative drug for the treatment of acute thrombotic diseases, including the acute phase of ischemic stroke.
The drug candidate of Acticor Biotech, glenzocimab (ACT017) is evaluated in the ACTIMIS Trial (NCT03803007) an international, multi-center phase 1b/2a clinical study to assess the safety of glenzocimab in Acute Ischemic Stroke as an add-on therapy to the Standard of Care.
In 2020, rising to respond to the challenge of global COVID-19 pandemic, Acticor Biotech initiated a phase 2 international clinical study (GARDEN, NCT04659109), assessing glenzocimab in the treatment of acute respiratory distress syndrome (ARDS) in SARS-Cov-2 infected patients.Learn more on Acticor Biotech
13.7 Million strokes in the world
In 2016, 13.7 million strokes occurred in the world. Each year, around one million patients in Europe experience a stroke and approximately 800,000 in the USA (one every 40 seconds). In Europe, the Health Economics Research Centre of Oxford has estimated that incidence of stroke will rise of 34% by 2035.Learn more
2nd Cause of Death
Stroke is the 2nd cause of death worlwide with an estimated 5.5 millions deaths in 2016 and a leading cause of acquired disabilities in adults.Learn more
Major Economic Impact
In the USA stroke-related costs were 103 billion dollars (2016). In the EU countries, the total annual costs of stroke is estimated at 60 billion euros (2017).Learn more
Unmeet medical needs in acute ischemic stroke
Current pharmaceutical treatment of stroke are not fully satisfactory. Around 15% of patients can be treated with thrombolysis (alteplase) during the first hours after symptoms onset (4,5 hours in Europe, 3 hours in USA). Mechanical thrombectomy used since 2015 has demonstrated a 50% efficacy but only in a subpopulation of patients.
A first-in class antithrombotic drug
Glenzocimab: an antithrombotic agent with limited bleeding risk. Glenzocimab development is initially conducted as an add-on therapy to the approved standard of care in the acute phase of Ischemic Stroke.
Novel therapeutic target
Glenzocimab is directed against a novel target of major interest, platelet glycoprotein VI (GPVI) and inhibits its action. Activation of GPVI on the surface of platelets triggers platelet aggregation, the recruitment of additional platelets and results in activity that promotes coagulation. Additionally, GPVI plays a minor role in haemostasis, thus its inhibition will not cause hemorrhage.